New York-Presbyterian Hospital: 8-Week Oral Drug Treatment Cures Hepatitis C Infection in 98% of Patients With Compensated Cirrhosis
January 11, 2020
January 11, 2020
NEW YORK, Jan. 11 -- New York-Presbyterian Hospital issued the following news release:
An eight-week course of treatment with the daily oral drug glecaprevir/pibrentasvir cured chronic hepatitis C virus (HCV) infection in 98% of previously untreated patients with an asymptomatic form of cirrhosis or liver scarring known as compensated cirrhosis, according to the results of an international phase 3b clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian.
. . .
An eight-week course of treatment with the daily oral drug glecaprevir/pibrentasvir cured chronic hepatitis C virus (HCV) infection in 98% of previously untreated patients with an asymptomatic form of cirrhosis or liver scarring known as compensated cirrhosis, according to the results of an international phase 3b clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian.
. . .